Literature DB >> 17598812

Humoral immunity to HIV-1: neutralization and beyond.

M Huber1, A Trkola.   

Abstract

Humoral immunity is considered a key component of effective vaccines against HIV-1. Hence, an enormous effort has been put into investigating the neutralizing antibody response to HIV-1 over the past 20 years which generated key information on epitope specificity, potency, breadth and in vivo activity of the neutralizing antibodies. Less clear is still the role of antibody-mediated effector functions (antibody-dependent cellular cytotoxicity, phagocytosis, complement system) and uncertainty prevails whether Fc-mediated mechanisms are largely beneficial or detrimental for the host. The current knowledge on the manifold functions of the humoral immune response in HIV infection, their underlying mechanisms and potential in vaccine-induced immunity will be discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17598812     DOI: 10.1111/j.1365-2796.2007.01819.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  52 in total

1.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

2.  CD59 incorporation protects hepatitis C virus against complement-mediated destruction.

Authors:  Tohti Amet; Marwan Ghabril; Naga Chalasani; Daniel Byrd; Ningjie Hu; Ayslinn Grantham; Ziqing Liu; Xuebin Qin; Johnny J He; Qigui Yu
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

3.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Authors:  Andreas Mörner; Marianne Jansson; Evelien M Bunnik; Jørgen Schøller; Robert Vaughan; Yufei Wang; David C Montefiori; Nel Otting; Ronald Bontrop; Lesley A Bergmeier; Mahavir Singh; Richard T Wyatt; Hanneke Schuitemaker; Gunnel Biberfeld; Rigmor Thorstensson; Thomas Lehner
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

4.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

5.  Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals.

Authors:  Mary Dawn T Co; John Cruz; Akira Takeda; Francis A Ennis; Masanori Terajima
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

6.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

7.  Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.

Authors:  Lilin Lai; Suefen Kwa; Pamela A Kozlowski; David C Montefiori; Guido Ferrari; Welkin E Johnson; Vanessa Hirsch; Francois Villinger; Lakshmi Chennareddi; Patricia L Earl; Bernard Moss; Rama Rao Amara; Harriet L Robinson
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

8.  Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys.

Authors:  M Genescà; P J Skinner; K M Bost; D Lu; Y Wang; T L Rourke; A T Haase; M B McChesney; C J Miller
Journal:  Mucosal Immunol       Date:  2008-03-05       Impact factor: 7.313

9.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

10.  Toll-like receptor 7 inhibits early acute retroviral infection through rapid lymphocyte responses.

Authors:  Edward P Browne
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.